Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety.

Massimo Martino, Virginia Naso, Gaetana Porto, Annalisa Paviglianiti, Anna Ferreri, Barbara Loteta, Tiziana Moscato, Giuseppe Console, Massimo Gentile, Marco Rossi, Pasquale Fabio Provenzano, Mercedes Gori, Anna Lisa Pitino, Antonella Morabito, Giovanni Tripepi

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2021;59(6):102911

PMID: 32859502

Full Text on Elsevier Science View on PubMed

Abstract

PURPOSE

Cyclophosphamide (CY) in a dose of 2-4 g/m is widely used for hemopoietic progenitor stem cells mobilization. CY administration is associated with several adverse effects, including chemotherapy-induced nausea and vomiting (CINV). This study aimed to evaluate the efficacy and tolerability of granisetron transdermal system (GTDS) plus dexamethasone in the management of CINV in MM patients undergoing chemo-mobilization with CY.

METHODS

In this single-center, prospective, observational, real world study, GTDS plus dexamethasone was administered to MM patients receiving chemo-mobilization based on CY 2 g/m2 plus G-CSF in an outpatient setting. The rate of complete response was evaluated as the main outcome. Other outcomes were rate of complete control of CINV, incidence of nausea/vomiting of any grade and safety.

RESULTS

A total of 88 patients were enrolled. A complete response was achieved in 45.5 % of patients; among them, 39.77 % attained complete control of CINV. Nausea and vomiting never occurred in 34.1 % and 45.5 % of patients, respectively. No episodes of grade 3-4 nausea and/or vomiting were documented. GTDS was safe and well tolerated.

CONCLUSION

In real world, GTDS provided an innovative, effective, and well-tolerated control of CINV in MM patients after chemo-mobilization with CY. The study found out effectiveness of a non-invasive delivery system of antiemetic.

Address: Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy. Electronic address: [email protected].; Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.; Hematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy.; Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy.; CNR-IFC, Rome, Italy.; Pharmacy Unit, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.; CNR-IFC, Research Unit of Reggio Calabria, Reggio Calabria, Italy.

DOI: 10.1016/j.transci.2020.102911

Link outs

Free resources

Medical:

https://medlineplus.gov/nauseaandvomiting.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Administration, Cutaneous, Adolescent, Adult, Aged, Dexamethasone, Female, Granisetron, Humans, Male, Middle Aged, Multiple Myeloma, Nausea, Prospective Studies, Vomiting, Young Adult